The ACE and I: How ACE inhibitors came to be

FASEB Journal

Volumn 20, Issue 8, 2006, Pages 1034-1038

  Erdös, Ervin G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ARGININE; BRADYKININ; CAPTOPRIL; DIMERCAPROL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HISTIDINE; KALLIDIN; KALLIKREIN; LEUCINE; PHENYLALANINE; PLASMA PROTEIN; RAMIPRIL; RENIN; TEPROTIDE; NEUROPEPTIDE;

DRUG MECHANISM; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; PRIORITY JOURNAL; PROTEIN METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ARTICLE; HISTORY; METABOLISM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEUROPEPTIDES; PEPTIDYL-DIPEPTIDASE A;

EID: 33746029382     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-0602ufm     Document Type: Review

References (63)

1. Tigerstedt, R., and Bergman, P. G. (1898) Niere und Kreislauf. Skand. Arch. Physiol. 8, 223-227
2. Bouchard, C. (1884) Recherches experimentales sur la toxicite des urines normales. Compl. Rend. 8, 665-671
3. Webster, M. E. (1970) Kallikreins in glandular tissues. In Bradykinin, Kallidin and Kallikrein. Handbook of Experimental Pharmacology. (Erdös, E. G., ed) Vol. XXV, pp. 131-155, Springer Verlag, Berlin
4. Werle, E. (1970) Discovery of the most important kallikreins and kallikrein inhibitors. In Bradykinin, Kallidin and Kallikrein. Handbook of Experimental Pharmacology. (Erdös, E. G., ed) Vol. XXV, pp. 1-6, Springer Verlag, Berlin
5. Page, I. H. (1988) Hypertension Research. A Memoir 1920-1960, pp. 113, 122, Pergamon Press, New York
6. Frey, E. K., Kraut, H., and Werle, E. (1950) Kallikrein: Padutin, Ferdinand Enke Verlag, Stuttgart
7. Webster, M. E., and Pierce, J. V. (1963) The nature of the kallidins released from human plasma by kallikreins and other enzymes. In Structure and function of biologically active peptides: Bradykinin, kallidin, and congeners. (Erdös, E. G., ed) Vol. 104, pp. 91-107, The New York Academy of Sciences, New York
8. Beraldo, W. T., and Andrade, S. P. (1997) Discovery of bradykinin and the kallikrein-kinin system. In The Kinin System (Farmer, S. G., ed) pp. 1-8, Academic Press Ltd., San Diego
9. Skeggs, L. T., Dorer, F. E., Kahn, J. R., Lentz, K. E., and Levin, M. (1981) Experimental renal hypertension: the discovery of the renin-angiotensin system. In Biochemical Regulation of Blood Pressure (Soffer, R., ed) pp. 3-38, John Wiley & Sons, Inc., Hoboken
10. Skeggs, L. T., Jr. (2000) Persistence . . . and prayer: from the artificial kidney to the AutoAnalyzer. Clin. Chem. 46, 1425-1436
11. Ng, K. K. F., and Vane, J. R. (1968) Fate of angiotensin I in the circulation. Nature 218, 144-150
12. Vane, J. R. (1969) The release and fate of vaso-active hormones in the circulation. Br. J. Pharmacol. 35, 209-242
13. Erdös, E. G., and Yang, H. Y. T. (1967) An enzyme in microsomal fraction of kidney that inactivates bradykinin. Life Sci. 6, 569-574
14. Yang, H. Y. T., and Erdös, E. G. (1967) Second kininase in human blood plasma. Nature 215, 1402-1403
15. Yang, H. Y. T., Erdös, E. G., and Levin, Y. (1970) A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim. Biophys. Acta 214, 374-376
16. Yang, H. Y. T., Erdös, E. G., and Levin, Y. (1971) Characterization of a dipeptide hydrolase (kininase II; angiotensin I converting enzyme). J. Pharmacol. Exper. Therap. 177, 291-300
17. Igic, R., Erdös, E. G., Yeh, H. S. J., Sorrels, K., and Nakajima, T. (1972) The angiotensin I converting enzyme of the lung. Circul. Res. 31, II-51-61
18. Oshima, G., Gecse, A., and Erdös, E. G. (1974) Angiotensin I converting enzyme of the kidney cortex. Biochim. Biophys. Acta 350, 26-37
19. Bakhle, Y. S. (1968) Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 220, 919-921
20. Igic, R., Nakajima, T., Yeh, H. S. J., Sorrells, K., and Erdös, E. G. (1973) Kininases. Symposium on Kinin Peptides. Fifth Internat. Congress Pharmacol., 1972. San Francisco. In Pharmacology and the Future of Man (Acheson, G. H., ed) Vol. 5, pp. 307-319, Karger, Basel
21. Jaspard, E., Wei, L., and Alhenc-Gelas, F. (1993) Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem. 268, 9496-9503
22. Corvol, P., Eyries, M., and Soubrier, F. (2004) Peptidyl-dipeptidase A/angiotensin I-converting enzyme. In Handbook of Proteolytic Enzymes 2nd ed. (Barrett, A. J., Rawlings, N. D., and Woessner, J. F., eds) Vol. 1, pp. 332-346, Academic Press, San Diego
23. Wei, L., Alhenc-Gelas, F., Corvol, P., and Clauser, E. (1991) The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266, 9002-9008
24. Erdös, E. G., and Skidgel, R. A. (1997) Metabolism of bradykinin by peptidases in health and disease. In The Kinin System (Farmer, S. G., ed) pp. 111-141, Academic Press Ltd., San Diego
25. Erdös, E. G. (2004) Peptides and the enzymes that release or inactivate them. A short history of my life and work entwined. In A History of Biochemistry. Selected Topics in the History of Biochemistry. Personal Recollections VIII. (Semenza, G., and Turner, A. J., eds) pp. 279-354, Elsevier
26. Elliott, D. F. (1970) The discovery and characterization of bradykinin. In Bradykinin, Kallidin and Kallikrein. Handbook of Experimental Pharmacology. (Erdös, E. G., ed) Vol. XXV, pp. 7-13, Springer Verlag, Berlin
27. Erdös, E. G. (1966) Hypotensive peptides, bradykinin, kallidin and eledoisin. In Advances in Pharmacology (Garattini, S., and Shore, P. A., eds) Vol. IV, pp. 1-90, Academic Press, New York
28. Erdös, E. G. (1962) Enzymes that inactivate polypeptides. In Metabolic Factors Controlling Duration of Drug Action (Brodie, B. B., and Erdös, E. G., eds) pp. 159-178, Pergamon Press, New York
29. Ferreira, S. H., and Rocha e Silva, M. (1962) Potentiation of bradykinin by dimercaptopropanol (BAL) and other inhibitors of its destroying enzyme in plasma. Biochem. Pharmacol. 11, 1123-1128
30. Erdös, E. G., and Wohler, J. R. (1963) Inhibition in vivo of the enzymatic inactivation of bradykinin and kallidin. Biochem. Pharmacol. 12, 1193-1199
31. Ferreira, S. H. (1966) Bradykinin-potentiating factor. In Hypotensive Peptides. Proceedings of the International Symposium. Firenze, Italy, 1965. (Erdös, E. G., Back, N., and Sicuteri, F., eds) pp. 356-367, Springer-Verlag, New York
32. Ferreira, S. H., Bartelt, D. C., and Greene, L. J. (1970) Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9, 2583-2593
33. Ondetti, M. A., Williams, N. J., Sabo, E. F., Pluscec, J., Weaver, E. R., and Kocy, O. (1971) Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 10, 4033-4039
34. Kato, H., and Suzuki, T. (1970) Amino acid sequence of bradykinin-potentiating peptide isolated from the venom of Agkistrodon halys blomhoffii. Proc. Jap. Acad. 46, 176-181
35. Smith, C. G., and Vane, J. R. (2003) The discovery of captopril. FASEB J. 17, 788-789
36. Gavras, H. (2004) The discovery of captopril: reply. FASEB J. 18, 225
37. Erdös, E. G. (2004) The discovery of captopril: reply. FASEB J. 18, 226
38. Smith, C. G., and Vane, J. R. (2004) The discovery of captopril: a reply. FASEB J. 18, 935
39. Gavras, H., Brunner, H. R., Laragh, J. H., Sealey, J. E., Gavras, I., and Vukovich, R. A. (1974) An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N. Engl. J. Med. 291, 817-821
40. Gavras, H., Brunner, H. R., Turini, G. A., Kershaw, G. R., Tifft, C. P., Cuttelod, S., Gavras, I., Vukovich, R. A., and McKinstry, D. N. (1978) Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N. Engl. J. Med. 298, 991-995
41. Gavras, H. P., Faxon, D. P., Berkoben, J., Brunner, H. R., and Ryan, T. J. (1978) Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 58, 770-776
42. Cushman, D. W., Cheung, H. S., Sabo, E. F., and Ondetti, M. A. (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16, 5484-5491
43. Hooper, N. M., and Turner, A. J. (2003) An ACE structure. Nat. Struct. Biol. 10, 155-157
44. Patchett, A. A., and Cordes, E. H. (1985) The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin converting enzyme. Adv. Enzymol. Relat. Areas Mol. Biol. 57, 1-84
45. Pfeffer, M. (2001) Angiotensin-converting enzyme (ACE) inhibitors in the prevention of cardiovascular disease: Clinical evidence. In Angiotensin- Converting Enzyme (ACE):Clinical and Experimental Insights (Giles, T. D., ed) pp. 219-225, Health Care Communications, Inc., Fort Lee, NJ
46. Kirschner, M. W. (2005) The meaning of systems biology. Cell 121, 503-504
47. Erdös, E. G., Renfrew, A. G., Sloan, E. M., and Wohler, J. R. (1963) Enzymatic studies on bradykinin and similar peptides. In Structure and function of biologically active peptides: Bradykinin, kallidin, and congeners. (Erdös, E. G., ed) Vol. 104, pp. 222-234, The New York Academy of Sciences, New York
48. Erdös, E. G., and Yang, H. Y. T. (1966) Inactivation and potentiation of the effects of bradykinin. In Hypotensive Peptides. Proceedings of the International Symposium. Firenze, Italy, 1965. (Erdös, E. G., Back, N., and Sicuteri, F., eds) pp. 235-251, Springer-Verlag, New York
49. Gafford, J. T., Skidgel, R. A., Erdös, E. G., and Hersh, L. B. (1983) Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry 22, 3265-3271
50. Chen, Z., Tan, F., Erdös, E. G., and Deddish, P. A. (2005) Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors. Hypertension 46, 1368-1373
51. Tan, F., and Erdös, E. G. (2004) Lysosomal Pro-X carboxypeptidase. In ref. 23, pp. 1936-1938
52. Turner, A. J., and Hooper, N. M. (2004) Angiotensin-converting enzyme 2. In Handbook of Proteolytic Enzymes 2nd ed. (Barrett, A. J., Rawlings, N. D., and Woessner, J. F., eds) Vol. 1, pp. 349-352, Academic Press, San Diego
53. Skidgel, R. A., and Erdös, E. G. (1993) Biochemistry of angiotensin converting enzyme. In The Renin-Angiotensin System. (Robertson, J. I. S., and Nicholls, M. G., eds) Vol. 1, pp. 10.1-10.10, Gower Medical Publishers, London
54. Ferrario, C. M., and Chappell, M. C. (2004) Novel angiotensin peptides. Cell. Mol. Life Sci. 61, 2720-2727
55. Bhoola, K. D., Figueroa, C. D., and Worthy, K. (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1-80
56. Regoli, D., and Barabe, J. (1980) Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32, 1-46
57. Ignjatovic, T., Tan, F., Brovkovych, V., Skidgel, R. A., and Erdös, E. G. (2002) Novel mode of action of angiotensin I converting enzyme inhibitors. Direct activation of bradykinin B1 receptor. J. Biol. Chem. 277, 16847-16852
58. Ignjatovic, T., Stanisavljevic, S., Brovkovych, V., Skidgel, R. A., and Erdös, E. G. (2004) Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol. Pharmacol. 66, 1310-1316
59. Peng, H., Carretero, O. A., Vuljaj, N., Liao, T. D., Motivala, A., Peterson, E. L., and Rhaleb, N. E. (2005) Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 112, 2436-2445
60. Soubrier, F., Wei, L., Hubert, C., Clauser, E., Alhenc-Gelas, F., and Corvol, P. (1993) Molecular biology of the angiotensin I converting enzyme: II. Structure-function. Gene polymorphism and clinical implications. J. Hypertens. 11, 599-604
61. Rubin, B., Laffan, R. J., Kotler, D. G., O'Keefe, E. H., Demaio, D. A., and Goldberg, M. E. (1978) SQ14,225 (D-3-mercapto-2-methylpropanoyl-L-proline), a novel orally active inhibitor of angiotensin I-converting enzyme. J. Pharmacol. Exp. Ther. 204, 271-280
62. Marcic, B., Deddish, P. A., Skidgel, R. A., Erdös, E. G., Minshall, R. D., and Tan, F. (2000) Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors. J. Biol. Chem. 275, 16110-16118
63. Hemming, M. L., and Selkoe, D. J. (2005) Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem. 280, 37644-37650